Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than ...
Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...
and Viking Therapeutics is pushing its drug candidate to the forefront with early clinical data that have some analysts calling it potentially best in the class of emerging oral obesity drugs.
Key Takeaways Novo Nordisk's U.S.-listed shares rose Wednesday morning as third-quarter profits beat estimates and sales of Ozempic and Wegovy continued to grow.Sales rose 21% from the same time last ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback